For personal use only

ASX Announcement – 4 November 2026

APPOINTMENT OF HEAD OF CLINICAL SITE DEVELOPMENT & EXPANSION TO LEAD TRIALSWEST EAST-COAST NETWORK

Highlights

- **Experienced clinical operations leader appointed Head of Clinical Site Development & Expansion, leading the TrialsWest east-coast network, commencing 1 Dec 2026**
- **More than 25 years' experience across investigator sites, research governance, global pharma & biotech**
- **Role funded by the recent Placement (referenced as East-Coast General Manager in the Placement investor presentation released to the ASX on 27 Oct 2026)**
- **Site identification has commenced in target geographies, with the first east coast sites expected to open from H2 FY27 at a rate of approximately two a year**
- **East coast network to leverage TrialsWest's 20+ existing active trials and strong relationships with pharmaceutical and CRO clinical trial sponsors**

Experienced Clinical Operations Leader to Lead TrialsWest East-Coast Expansion

Resonance Health Limited (ASX: RHT) (**Resonance** or **Company**) announces the appointment of an experienced clinical operations leader as 'Head of Clinical Site Development & Expansion', leading the east-coast expansion of the Company's TrialsWest clinical trial site network (**Appointment**). The Appointment will formally commence on 1 December 2026.

Background

The Appointment is of an experienced executive leader (**Executive**) with more than 25 years' experience across the clinical trial ecosystem, spanning investigator sites, research governance, global pharma and biotech.

Most recently, the Executive was employed by a clinical-stage biotechnology company, where they were accountable for clinical research activities across Phase I-III studies.

Prior to that, the Executive worked for a global pharmaceutical company where they built the company's Australian study start-up capability, led site intelligence and investigator engagement for global study placement, and accelerated protocol receipt to the clinical trial's first-subject-visit.

The Executive's earlier experience included research governance across public and private health networks and contributing to state health policy reforms that streamlined ethical review of multicentre research.

A registered nurse by background, the Executive is based on the east-coast.

Resonance Health Ltd ABN: 96 006 762 492
141 Burswood Road, Burswood, WA 6100, AUSTRALIA
www.resonancehealth.com **T** + 61 8 9286 5300
Postal: PO Box 108, Victoria Park, WA 6979, AUSTRALIA
info@resonancehealth.com

TrialsWest East Coast Expansion

The new Executive will serve as TrialsWest's dedicated east-coast leader, as reported in the Company's capital raising investor presentation released to ASX on 27 October 2026.

The east-coast expansion strategy largely replicates TrialsWest's west-coast site model on the east-coast, with Resonance Health and TrialsWest aiming to build a nine-site national network: the three existing sites in Western Australia (**WA**) (Spearwood, Osborne Park, and Mandurah) plus six-new east-coast sites, run in a 'hub-and-spoke' model from TrialsWest's headquarters.

The model is established and has been proven in WA. TrialsWest generated $4.1[1] million of revenue from its three WA sites in FY26 with Osborne Park generating $2 million annualised run-rate in only its third year, and Mandurah close to achieving breakeven in its first year.

Site identification has commenced in the Company's targeted east-coast regions. The east-coast network will leverage TrialsWest's 20+ active trials and its strong relationships with clinical trial sponsors, comprised of both global pharmaceutical companies and contract research organisations (**CROs**). Each new site will require ~$100,000 of fit-out capex and two FTE including a Principal Investigator who will be engaged before each site is committed.

The first east-coast sites are expected to open from the second half of FY27 (January to June 2027), at a rate of approximately two a year. New clinical trial sites are excluded from the Company's FY27 guidance.

Resonance Health's CEO & Managing Director, Mr Andrew Harrison said:

"Our new Head of Clinical Site Development &Expansion has spent more than 25 years on every side of a clinical trial – from the hospital bedside to investigator sites, research governance, global pharma and biotech – building start-up capability from scratch and learning exactly what sponsors look for when they place a study. This is what the east-coast rollout needs.

TrialsWest has built its business in Western Australia on strong pharma and CRO relationships. The east-coast network will receive workflow from these sponsors and the studies we already run for them, not from a standing start. Taking that model east is growth inside our domain. Site identification is underway, and from 1 December 2026 the job is execution."

Further Information

https://investors.resonancehealth.com

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Limited.

For further information:
Andrew Harrison
Managing Director & CEO
E: andrewh@resonancehealth.com
P: +61 8 9286 5300

[1] Revenue before intercompany eliminations

For personal use only

About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high-quality quantitative assessments essential in managing diseases and drug development.

Resonance Health's dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (SaMDs) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (AI), include:

- **FerriScan®,** a core-lab product that provides an accurate assessment of liver iron concentration (LIC) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®,** an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in participants, calibrated against the global gold standard, FerriScan®.
- **HepaFatScan®,** an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFatSmart®,** an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in participants, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®,** an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2*,** the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*.

The Company has a development pipeline of additional medical imaging analysis products and services, including the MRI Liver Fibrosis Project, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis. The Company also has a clinical trials business which both manages clinical trials in Australia and includes the site management operations of TrialsWest.

Stakeholders, including clinicians, participants, and shareholders, are encouraged to follow Resonance Health on LinkedIn and register their interest at www.resonancehealth.com

Disclaimer & Forward-Looking Statements

This announcement has been prepared by Resonance Health Ltd ("Resonance Health" or "Company") and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause actual results to differ materially from those described. Forward looking statements contained in this release may include statements about future financial and operating results, status of regulatory submissions, possible or assumed future growth opportunities and risks and uncertainties that could affect Resonance Health's products and services.

These forward-looking statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may prove inaccurate. Actual outcomes and results may differ materially from what is expressed in any forward-looking statement in which Resonance Health expresses an expectation or belief as to future results. There can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. Resonance Health will not update forward-looking statements unless required by law.

For personal use only